# A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

> **NCT05800665** · PHASE1 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 210 (estimated)

## Conditions studied

- Advanced Prostate Cancer
- Metastatic Prostate Cancer

## Interventions

- **DRUG:** RO7656594

## Key facts

- **NCT ID:** NCT05800665
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-02
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05800665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05800665, "A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT05800665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*